Skip to Main Content

Advertisement

Skip Nav Destination

Abstract LB-303: Anti-IGF1R therapy with dalotuzumab is efficacious in pre-clinical models of erlotinib refractory NSCLC

Cancer Res (2010) 70 (8_Supplement): LB-303.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal